Skip to content

The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00674843
Enrollment
4
Registered
2008-05-08
Start date
2008-05-31
Completion date
2010-06-30
Last updated
2009-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscular Dystrophies

Keywords

MYOTONIC DYSTROPHY, MYOPATHIES, Distal Myopathies, Muscular Dystrophy, Duchenne, Phosphorylase Deficiency (McArdle Disease)

Brief summary

The muscular dystrophies (MD) are a group of more than 30 neuromuscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins and the death of muscle cells and tissue. This study will investigate the use of far infrared radiation for managing muscular dystrophies.

Detailed description

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly cure these neuromuscular disorders.

Interventions

Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.

Sponsors

GAAD Medical Research Institute Inc.
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Persons with muscular dystrophies

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Management and Cure of muscular dystrophies2 Years

Secondary

MeasureTime frame
Rehabilitation of people with muscular dystrophies2 Years

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026